PTER

Across TCGA pan-cancer cohorts, PTER mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTER data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PTER mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PTER expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where PTER mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.510	0.295	.001	32	view →
HNSC	DFS	Quartile	All	0.883	1.000	.007	12	view →
CCRCC	OS	Median	II,III,IV	1.000	0.499	.025	11	view →
LSCC	DFS	Quartile	II,III,IV	0.414	0.801	.017	9	view →
GBM	OS	Median	All	0.430	0.642	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTER–PDAC (DFS)

Open the PDAC breakdown →